<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DEXMEDETOMIDINE HYDROCHLORIDE</span><br/>(dex-med-e-to'mi-deen)<br/><span class="topboxtradename">Precedex<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha<sub>2</sub>-adrenergic agonist (sympathomimetic)</span>; <span class="classification">sedative-hypnotic</span><br/><b>Prototype: </b>Methoxamine HCl<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mcg/mL in 2 mL ampule or vial</p>
<h1><a name="action">Actions</a></h1>
<p>A selective alpha<sub>2</sub>-adrenergic agonist with sedative properties. Dexmedetomidine stimulates alpha<sub>2</sub>-adrenergic receptors in the CNS (primarily in the medulla oblongata) causing inhibition of the sympathetic vasomotor center
         of the brain.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Sedative properties utilized in intubating patients and for initially maintaining them on a mechanical ventilator. Hemodynamic
         responses of the heart affected by alpha<sub>2</sub> receptors are better controlled with dexmedetomidine than with other related drugs (e.g., midazolam).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Sedation of initially intubated or mechanically ventilated patients.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to dexmedetomidine; labor and delivery, including cesarean section.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with arrhythmias or cardiovascular disease; renal or hepatic insufficiency; signs of light anesthesia; pregnancy
         (category C), lactation; older adults &gt;65 y. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Start with 1 mcg/kg infused over 10 min, then continue with infusion of 0.20.7 mcg/kg/hr for up to 24 h, may need to
               decrease dosage in patients with renal or hepatic impairment<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Withdraw 2 mL of dexmedetomidine and add to 48 mL of 0.9% NaCl injection. Shake gently to mix.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Administer using a controlled infusion device. A loading dose of 1 mcg/kg is infused over 10 min followed by the ordered maintenance
                  dose. Do <b><small>NOT</small></b> use administration set containing natural rubber. Do <b><small>NOT</small></b> infuse longer than 24 h.  
               </p>
<ul>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Pain, infection. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension,</span> bradycardia, atrial fibrillation. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> thirst. <span class="typehead">Respiratory:</span> Hypoxia, pleural effusion, pulmonary edema. <span class="typehead">Hematologic:</span> Anemia, leukocytosis. <span class="typehead">Urogenital:</span> Oliguria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification"> barbiturates</span>, <span class="classification">benzodiazepines</span>, <span class="classification">general anesthetics</span>, <span class="classification">opiate agonists</span>, <span class="classification">anxiolytics</span>, <span class="classification">sedatives/hypnotics</span>, <b>ethanol,</b> <span class="classification">tricyclic antidepressants</span>, <b>tramadol,</b> <span class="classification">phenothiazines</span>, <span class="classification">skeletal muscle relaxants</span>, <b>azatadine,</b> <b>brompheniramine,</b> <b>carbinoxamine,</b> <b>chlorpheniramine,</b> <b>clemastine,</b> <b>cyproheptadine,</b> <b>dexchlorpheniramine,</b> <b>dimenhydrinate,</b> <b>diphenhydramine,</b> <b>doxylamine,</b> <b>hydroxyzine,</b> <b>methdilazine,</b> <b>phenindamine,</b> <b>promethazine,</b> <b>tripelennamine</b> enhance CNS depression possibly prolong recovery from anesthesia. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Half-life 6 min. <span class="typehead">Metabolism:</span> Extensively metabolized in the liver (CYP 2A6). <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for hypertension during loading dose; reduction of loading dose may be required.</li>
<li>Monitor cardiovascular status continuously; notify physician immediately if hypotension or bradycardia occur.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>